Regulation of the intestinal immune system by flavonoids and its utility in chronic inflammatory bowel disease

Harald Peter Hoensch, Benno Weigmann

Abstract

Flavonoids are phytochemicals which can regulate the activity of the intestinal immune system. In patients with chronic inflammatory bowel disease (IBD) there is an overexpression and imbalance of the components of the inflammatory immune reactions which are chronically activated. Suppression of inflammation can be achieved by anti-inflammatory drugs which are used in clinical medicine but these can cause serious side effects. Flavonoids can have natural immunosuppressive properties and inhibit the activation of immune cells and its effectors (chemokines, TNF-, cytokines). Phytochemicals such as flavonoids bind to the nuclear Ah (aryl hydrocarbon) -receptor thereby stimulating protective enzyme activities. As shown by clinical evidence in patients and by experimental work some flavonoids (apigenin, epigallocatechin gallate) were effective in the inhibition of inflammation. Instead of or additionally to anti-inflammatory drugs flavonoids can be used in IBD patients to treat the over-reactive immunologic system. This is accomplished by upregulation of the Ah-receptor. Flavonoids interact with toll-like receptors expressing on the surface of immune cells, then they were internalized to the cytosol and transferred into the nucleus, where they were attached to the Ah-receptor. The Ah-receptor binds to the Ah-R nuclear translocator and via Ah response element beneficial protective enzymes and cytokines are induced, leading to upregulation of the anti-inflammatory system.

Key words: Flavonoids; Inflammatory bowel disease; Ah-receptor

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Overview regulation of the intestinal immune system by flavonoids and its utility in chronic
Inflammatory bowel disease.

Hoensch HP, Weigmann B. Regulation of the intestinal immune system by flavonoids and its utility in chronic inflammatory bowel disease. World J Gastroenterol 2018; 24(8): 877-881 Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i8/877.htm DOI: http://dx.doi.org/10.3748/wjg.v24.i8.877

INTRODUCTION
Disturbances of the intestinal immune system can lead to chronic inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis (UC)[1,2]. Inappropriate chronic stimulation of the native and adaptive immune system induces an inflammatory reaction of the epithelial mucosa in the rectum, as well as in small and large bowel. There exists only limited evidence about the cause of this reaction which includes bacterial overproduction, defective barrier function, genetic and environmental aberrations.

PATHOPHYSIOLOGY
While the pathophysiology of the inflammatory changes is quite well explained the level of the immune reaction is not sufficiently delineated. This level might be determined by factors which regulate the degree of the immune reactions. These regulatory factors could be responsible for the activity of the inflammatory immune reaction and should be identified. Phytochemicals and among them polyphenols and flavonoids can influence various components of immune system and thereby determine the disease activity in IBD and in experimental colitis[3,4].

There is a plethora of clinical studies and experimental results on the association between colorectal cancer (CRC)[5] and exposure to phytochemicals especially flavonoids[6]. It is still not yet clear whether these xenobiotics could play a role in the development of intestinal neoplasia. Most studies indicate that dietary components from fruits and vegetables lower the risk of CRC and other tumors[7,8]. Flavonoids among other phytochemicals could prevent CRC[9] and its precursors (colonic adenomas, dysplasia and aberrant crypt foci) by long term preneoplastic dietary exposure. It is now accepted that chronic inflammatory changes of the intestinal mucosa predate neoplasia and that treatment of the inflammation and identification of its etiologic factors are necessary for cancer prevention.

ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS
In chronic inflammatory reactions the intestinal mucosa and the submucosa contain 2 components which are responsible for immune activation: The innate system and the adaptive system both of which contribute to the degree of activation. Whereas immune cells such as dendritic cells, granulocytes, macrophages, natural killer cells and mast cells belong to the innate immune system the adaptive system includes T-lymphocytes, B-lymphocytes and plasma cells and immunoglobulins. Innate immunocytes are activated into myeloid and plasmacytoid dendritic cells. Naive lymphocytes are activated into T-helper cells, cytotoxic T-cells, regulatory T-cells and active B-cells. Inflammatory signals are the main factors for immune activation. Flavonoids are natural inhibitors and can prevent the activation of the innate and adaptive immune system[10]. Some flavonoids such as tea flavonoids (apigenin and epigallocatechin gallate) have been found to prevent the activation of immune cells and its effectors (chemokines, TNF-α and cytokines)[11].

In vivo the anti-inflammatory effects were shown by inhibition of transcriptions factors like nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells (NF-kB) and by suppression of cyclooxygenase 2 (COX-2) enzymes[12]. In patients with IBD chemokines and chemokine receptors are increased[13]. Phytochemicals have been shown to suppress inflammatory signal transduction systems leading to autophagy and apoptosis[14].

INFLUENCE OF FLAVONOIDS ON THE MICROBIOTA
Dysbalance of the microflora has been found in patients with IBD and chronic diarrhea[15]. The microbiota shows less variability and abundance of certain bacteria such as prevotellaceae and sulfide producing bacteria. Dietetic flavonoids can improve the fecal microbiota and prevent diarrhea. A recent study indicates that in pediatric patients the fecal microflora is related to diet and the composition of the microbiota indicates a pro-inflammatory status of IBD[16].

FLAVONOIDS AND MICROSOMAL ENZYMES
Dietary xenobiotics such as phytochemicals seem to be involved in the pathogenesis and treatment of chronic IBD[17]. Flavonoids are substrates for certain cytochrome P-450 enzymes (including CYP1A1) and are metabolized by components of the proteasome (P), endoplasmic reticulum (ER) and mitochondria (M), called PERM hypothesis[18]. This PERM concept defines the functional structure, which regulates the survival decision of cells under stress situation. Most probably this dynamic system can act as a single master tuner of cellular decisions about life or death, in order to give a chance to the remaining living cells in an organism. The ER consists of cytochrome P-450 enzymes (including CYP1A1) and conjugating enzymes which metabolically break down toxic compounds. Human cytochrome 3A4 and...
2C9 enzymes are inhibited by flavonoids in vitro but can also be induced in vivo\textsuperscript{[19,20]}. These enzymes could be biomarkers for the activity of the PERM system, indicate moderate beneficial induction and a favorable immune status. Flavonoid mediated induction is a positive event for the immune system boosting its anti-inflammatory activity. In the intestine of IBD patients the CYP 1A1 enzymes were upregulated\textsuperscript{[21]}.  

**FLAVONOIDS AND PERM**  
An intracellular mechanism exists for the detoxification of reactive oxygen radicals, which are taken care of by the proteasome, the ER and the mitochondria\textsuperscript{[18]} acting as PERM system. Flavonoids can activate this system as stressing and signaling molecules and are thereby responsible for the suppression of "pathologic" stress. Patients with IBD could probably benefit from dietary flavonoids supplementation\textsuperscript{[10,22]}.  

**FLAVONOIDS REGULATE THE AH-RECEPTOR**  
The aryl hydrocarbon receptor (Ahr) functions as intracellular transcription factor for the action of flavonoids and other phytochemicals such as indoles, isothiocyanates, cruciferous plants and cabbage products (Figure 1)\textsuperscript{[21]}. During the passage through the gastrointestinal tract digestion takes place and flavonoids are broken metabolically down into smaller molecules. FN (flavonoids) present in the gut lumen bind to the toll-like receptor of the plasma membrane and are transported into the cytosol. Here as a ligand they are attached to the Ahr and triggers translocation into the cell nucleus. Via dimerization with the Ahr nuclear translocator (Arnt) protein the ligand FN-Ahr-Arnt complex binds to the AhRE (Ah response Element) found in the 5 V flanking region of numerous genes. This element activates the target genes which are transcript into cytochrome P-450 and other protective enzymes. Additionally, regulatory T-cells, STAT3 and IL-22 are expressed and upregulated. The Ahr is localized mainly in lymphocytes and dendritic cells of the intestinal mucosa. Interleukin-22 is responsible for the intestinal integrity and the production of mucus and upregulation of beta-defensin-2\textsuperscript{[23]}. The FN ligand is the major immune modulator and induces a beneficial pattern of cytokines and immune cells which counteract the inflammatory alterations of the intestinal mucosa. In contrast to the biologicals these botanicals do not.

---

**Figure 1** Simplified scheme of the gene regulation by the aryl hydrocarbon receptor. Flavonoids bind to the toll-like receptor in the lumen and get internalized to the cytosol. Then the complex functions as a ligand for the Ah receptor, which results in the release of associated proteins and translocation to the nucleus followed by dimerization with Arnt. The Ahr/Arnt complex binds the AhRE promoting target gene transcription like upregulation of IL-22, cytochrome P-450 and PERM activity as well as downregulation of STAT3 and NF-κB. The ligands can also exert their effects in the cytoplasm through AHR-associated protein kinases to alter the function of a variety of proteins through a cascade of protein phosphorylation. Ahr: Aryl hydrocarbon receptor; Amt: Ahr nuclear translocator; Ah: Aryl hydrocarbon. FN: Flavonoid; TLR: Toll-like receptor; Ahr: Ah receptor; Amt: Ahr nuclear translocator; AhRE: Ah Response Element.
require an immunosuppressive therapy and constitute natural inducers of the immune system[24]. As plant products (xenobiotics) they could be used as an anti-inflammatory diet and could be beneficial for prevention and as nutritional supplements[10].

**EVIDENCE OF INHIBITION OF INTESTINAL INFLAMMATION BY FLAVONOIDS**

Diets could be beneficial in the treatment of IBD[25]. Dietary flavonoids could play a prominent role as part of a healthy diet[26]. There are several experimental studies which indicate the utility of flavonoids in models of chronic IBD[27-31]. Especially the effects on the various aspects and consequences of inflammation (barrier integrity and microbiota) have been explained. The therapeutic benefits of catechins are mediated by glutathione peroxidase, glutathione and by down-regulation of immune cells of the innate and induced system and their related signaling pathways (NF-κB, MAPK`s)[32].

Regular dietary consumption of green tea extract (epigallocatechin gallate) reduces DNA damage and increases the anti-oxidative capacity of blood plasma[33].

In UC chamomile extract (apigenin) given as a nutritional supplement was capable of remission maintenance. This was shown in a placebo controlled prospective trial[34]. In a similar study this could also be found for curcumin (which is a polyphenol) treatment.

Apigenin K was used in two different experimental colitis models and showed intestinal anti-inflammatory activity[35]. Furthermore, apigenin, as a nutritional supplementary flavonoid, can suppress NF-κB regulated expression of anti-apoptotic COX-2 and cFLIP in activated human T cells. Thus, apigenin is a possible interesting potent inhibitor which can be used for autoimmune inflammatory disease therapy, although the problem of bioavailability can be solved in the future[36].

In a study by Najafzadeh et al[37] flavonoids, especially quercetin and epicatechin, inhibits the DNA damage potency of H2O2 and IQ (quinoline) in lymphocytes isolated from IBD patients[38] in vitro experiments to 48% and 43% in comparison to controls. Here a concentration of 250 μg/mL quercetin and 100 μg/mL epicatechin is sufficient, respectively.

**CONCLUSION**

Flavonoids are able to influence the intestinal immune system and to regulate the strength and the pattern of the immune response in patients with chronic intestinal inflammation. Flavonoids drive the inflammatory cytokines into regression. The transcription factor Ah-R regulates the expression of target genes for the anti-inflammatory activity of the flavonoids.

Clinical trials in patients with IBD with valid endpoints to measure the outcome with and without flavonoid treatment are rare and should be done soon.

**REFERENCES**

1. Podolsky DK. Inflammatory bowel disease (1). *N Engl J Med* 1991; 325: 928-937 [PMID: 1881418 DOI: 10.1056/NEJM199109263251306]
2. Podolsky DK. Inflammatory bowel disease (2). *N Engl J Med* 1991; 325: 1008-1016 [PMID: 1886623 DOI: 10.1056/NEJM199110033251406]
3. Aldini R, Micucci M, Cevenini M, Fato R, Bergamini C, Nanni C, Cont M, Camborota C, Spinuzzi S, Montagnani M, Roda G, D’Errico-Grigioni A, Rosini F, Roda A, Mazzella G, Chiari A, Budresi R. Antiinflammatory effect of phytoestrogen in experimental murine colitis model: prevention, induction, remission study. *PloS One* 2014; 9: e108112 [PMID: 25268769 DOI: 10.1371/journal.pone.0108112]
4. Somani SJ, Modi KP, Majumdar AS, Sadarani BN. Phytochemicals and their potential usefulness in inflammatory bowel disease. *Phytother Res* 2015; 29: 339-350 [PMID: 25572840 DOI: 10.1002/ptr.5271]
5. Korfald E, Ebkom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. *Gut* 1997; 41: 522-525 [PMID: 9391253 DOI: 10.1136/gut.41.4.522]
6. Scalbert A, Zaman-Ros R. Bridging evidence from observational and intervention studies to identify flavonoids most protective for human health. *Am J Clin Nutr* 2015; 101: 897-898 [PMID: 25832341 DOI: 10.3945/ajcn.115.110205]
7. Li YH, Niu YB, Sun Y, Zhang F, Liu CX, Fan L, Mei QB. Role of phytochemicals in colorectal cancer prevention. *World J Gastroenterol* 2015; 21: 9262-9272 [PMID: 26309535 DOI: 10.3748/wjg.v21.i31.9262]
8. Schwingshackl L, Schwedhelm C, Hoffmann G, Knüppel S, Laure Preterre A, Iqbal K, Bechthold A, De Henauw S, Michels KA, Sommer F. Phytochemicals as natural inducers of the immune system and their related signaling pathways (NF-κB, MAPK`s) and colon cancer. *Curr Pharm Des* 2015; 21: 3939-3965 [PMID: 24478593 DOI: 10.1080/13816121.2012.687275]
9. Hoensch HP. Kirch W. Role potential of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. *Int J Gastrointest Cancer* 2005; 35: 187-195 [PMID: 1610120 DOI: 10.1385/IOGC:35:3:187]
10. Hoensch HP. Oertel R. The value of flavonoids for the human nutrition: Short review and perspectives. *Clinical Nutrition Experimental* 2015; 3: 8-14 [DOI:10.1016/j.clinuex.2015.09.001]
11. Cialdella-Kam L, Ghosh S, Meaney MP, Knab AM, Shanely RA, Nieman DC. Quercetin and Green Tea Extract Supplementation Downregulates Genes Related to Tissue Inflammatory Responses to a 12-Week High Fat-Diet in Mice. *Nutrients* 2017; 9: [PMID: 28753942 DOI: 10.3390/nu9070773]
12. Ruiz PA, Braune A, Holzwinmer G, Quintanilla-Fend L, Haller D. Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. *J Nutr* 2007; 137: 1208-1215 [PMID: 17445853 DOI: 10.1093/jn/137.5.1208]
13. Miyazaki H, Takabe K, Yuedall WA. Chemokines, chemokine receptors and the gastrointestinal system. *World J Gastroenterol* 2013; 19: 2847-2863 [PMID: 23704819 DOI: 10.3748/wjg.v19.i9.2847]
14. Talero E, Ávila-Roman J, Motivla V. Chemoprevention with phytoconstituents and microalgae products in chronic inflammation and colon cancer. *Curr Pharm Des* 2012; 18: 3939-3965 [PMID: 22632755 DOI: 10.2174/138161212802083275]
15. Magrone T, Tirillo E. The interplay between the gut immune system and microbiota in health and disease: nutraceutical intervention for restoring intestinal homeostasis. *Curr Pharm Des* 2013; 19: 1329-1342 [PMID: 23151182]
16. Sommer F, Rüüleleman MC, Bang C, Höppner M, Rehman A, Kaleta C, Schmitt-Kopplin P, Denephe A, Weidinger S, Ellinghaus WJG | www.wjgnet.com 880 February 28, 2018 | Volume 24 | Issue 8 |
